Tysabri effective for MS but carries some risk
Thu, 02 Mar 2006 01:15 AM EST
... NEW YORK (Reuters Health) - Tysabri, a drug made by Biogen Idec and Elan Pharmaceuticals, significantly reduces the rate of disease progression in patients with relapsing multiple sclerosis (MS), according to the results of two trials reported in this week''s New England Journal of Medicine. ...
Related Topics
- Tysabri
- Multiple Sclerosis
- Risk Factors
- Morphine ER
- Interferon Beta-1a Injection (Avonex
- Glatiramer Injection
- Security Risk Assessment
- Cardiac Risk
- High Risk Pregnancy
- Multiple Sclerosis/ms
- Youth Risk Behaviors
- Docusate
- CVD
- Youth Risk Behavior Surveillance System
- Memantine
- Dietary Risk Factors
- Cardiovascular Diseases And Disorders
- Coronary Disease
- Smoking Cessation and Continued Risk in Cancer Patients
- Coronary Artery Disease

Not Signed In -


